Drug intelligence / Profile preview

anti-CCL6 antibody

Development stage
Preclinical
Lead developer
Jiangsu Provincial People's Hospital
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intraperitoneal
01

Overview

An anti-CCL6 antibody is a neutralizing monoclonal antibody designed to target C-C motif chemokine ligand 6 (CCL6). In preclinical research concerning Crohn's disease, CCL6 has been identified as a critical pro-fibrotic mediator secreted by a specific subset of S100A8/A9-high macrophages. These macrophages activate intestinal fibroblasts via the CCL6-CCR1 signaling axis, driving the progression of intestinal fibrosis. By binding to and neutralizing CCL6, the antibody prevents its interaction with the CCR1 receptor, thereby inhibiting fibroblast activation and relieving established fibrosis in murine models of chronic colitis. While CCL6 is specific to rodents, its human ortholog is CCL15, which exerts comparable pro-fibrotic effects through the same CCR1 receptor, suggesting that targeting this axis may be a viable therapeutic strategy for treating fibrostenotic Crohn's disease in humans.

Other names
CCL6 antibodyCCL-6 antibodyCCL 6 antibodyanti-mCCL6 antibodyanti-mCCL-6 antibodyanti-mCCL 6 antibody
02

Targets

CCL (CC chemokine ligands)

Beyond the preview

Go deeper on anti-CCL6 antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-CCL6 antibody.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call